J&J to Pay as Much as $1.7B for Heart-Tech Firm V-Wave

The platform seeks to address limitations associated with existing cancer therapies and has generated preclinical candidates targeting multiple KRAS-driven solid tumor indications.

A routine provision in M&A agreements can expose sellers to uncapped liability—making precise drafting of “fraud” critical to post-closing risk allocation.

Endospan, headquartered in Israel, specializes in endovascular technologies designed to treat complex aortic arch disease.